PDUFA Calendar
The dates by which FDA has committed to decide on a drug, as companies have announced them.
FDA does not publish the dates by which it has agreed to decide on a drug; companies announce them. These are the dates companies have disclosed in their SEC filings, each with the filing's own sentence, and the advisory committee meetings ahead.
- Decision dates in the next 90 days: 19
- Next: Deramiocel, Capricor Therapeutics, Inc.: Nov 22, 2026
- Advisory committee meetings ahead: 1
Decision Dates by Month
Disclosed PDUFA dates in the next twelve months, as of Nov 17, 2026. Companies announce most dates within a year of the decision, so later months fill in.
Upcoming Decision Dates
41 disclosed dates ahead, soonest first. Each filing link opens the source; hover it to read the company's own sentence.| in 5 days | Deramiocelupper limb impairment in patients 9 years old | Capricor Therapeutics, Inc. | BLA | 8-K filed Nov 10, 2026 |
| in 10 days | BBP-418 | NDA | 10-Q filed Oct 29, 2026 | |
| in 11 days | D-PLEX 100 | PolyPid Ltd. | NDA | 6-K filed Nov 12, 2026 |
| in 13 days | povetaciceptIgA nephropathy | Jade Biosciences, Inc. Zai Lab Ltd | BLA | 10-Q filed Nov 3, 2026 |
| in 13 days | bezuclastinibgastrointestinal stromal tumor | Cogent Biosciences, Inc. | — | 8-K filed Aug 10, 2026 |
| in 25 days | imsidolimabgeneralized pustular psoriasis (GPP) | Anaptysbio, Inc. | BLA | 10-Q filed Nov 12, 2026 |
| in 30 days | relacorilantCushing's syndrome | NDA | 8-K filed Nov 3, 2026 | |
| in 35 days | lorundrostat | Mineralys Therapeutics, Inc. | NDA | 10-Q filed Nov 4, 2026 |
| in 36 days | anito-celmultiple myeloma | Arcellx, Inc. | BLA | 10-Q filed Aug 6, 2026 |
| in 40 days | relutrigine | Praxis Precision Medicines, Inc. | NDA | 10-Q filed Nov 9, 2026 |
| in 43 days | bezuclastinibnon-advanced systemic mastocytosis | Cogent Biosciences, Inc. | — | 8-K filed Aug 10, 2026 |
| in 48 days | IBTROZI | sNDA | 8-K filed Nov 4, 2026 | |
| in 65 days | Zeleciment rostudirsenDuchenne muscular dystrophy (DMD) | Dyne Therapeutics, Inc. | BLA | 8-K filed Nov 5, 2026 |
| in 72 days | ARIKAYCEMAC lung disease | sNDA | 10-Q filed Oct 29, 2026 | |
| in 73 days | ulixacaltamide HClessential tremor | Praxis Precision Medicines, Inc. | NDA | 10-Q filed Nov 9, 2026 |
| in 74 days | JoenjaAPDS | sNDA | 6-K filed Sep 25, 2026 | |
| in 77 days | Yeztugo (lenacapavir)HIV pre-exposure prophylaxis (PrEP) | sNDA | 10-Q filed Aug 6, 2026 | |
| in 79 days | infigratinib | NDA | 10-Q filed Oct 29, 2026 | |
| in 87 days | tinlarebantStargardt disease type 1 (STGD1) | Belite Bio, Inc. | NDA | 6-K filed Nov 12, 2026 |
| in 98 days | ZORYVE cream 0.05%atopic dermatitis in infants down to 3 months of age | sNDA | 8-K filed Nov 4, 2026 | |
| in 102 days | zipalertinibrelapsed epidermal growth factor receptor exon 20 insertion non-small cell lung cancer | Cullinan Therapeutics, Inc. | NDA | 8-K filed Nov 10, 2026 |
| in 103 days | QTORIN Rapamycinmicrocystic lymphatic malformations | Palvella Therapeutics, Inc. | — | 8-K filed Nov 5, 2026 |
| in 103 days | VOXZOGOachondroplasia | sNDA | 10-Q filed Nov 3, 2026 | |
| in 106 days | Zanzalintinibpreviously treated metastatic colorectal cancer | — | 8-K filed Oct 29, 2026 | |
| in 113 days | Lonvoguran Ziclumeran (Lonvo-z)Hereditary Angioedema (HAE) | Intellia Therapeutics, Inc. | BLA | 8-K/A filed Nov 13, 2026 |
| in 119 days | Anaphylm (dibutepinephrine)Type I allergic reactions, including anaphylaxis | NDA | 8-K filed Oct 15, 2026 | |
| in 135 days | Pitolisant GR | Harmony Biosciences Holdings, Inc. | NDA | 10-Q filed Nov 4, 2026 |
| in 148 days | ozekibartconventional chondrosarcoma | Inhibrx Biosciences, Inc. | BLA | 8-K filed Aug 13, 2026 |
| in 150 days | oral cannabidiol capsule formulation | NDA | 8-K filed Nov 2, 2026 | |
| in 156 days | IdvynsoHIV-1 infection | sNDA | 10-Q filed Nov 4, 2026 | |
| in 157 days | Deucrictibant IR | Pharvaris N.V. | NDA | 6-K filed Aug 12, 2026 |
| in 162 days | varegacestat | Immunome Inc. | NDA | 10-Q filed Nov 9, 2026 |
| in 165 days | ifezuntirgene inilparvovec | uniQure N.V. | BLA | 10-Q filed Nov 4, 2026 |
| in 165 days | AXS-12cataplexy in narcolepsy | NDA | 10-Q filed Nov 2, 2026 | |
| in 172 days | encaleret | NDA | 10-Q filed Oct 29, 2026 | |
| in 177 days | Mezigdomide | — | 8-K filed Oct 29, 2026 | |
| in 191 days | obexelimabImmunoglobulin G4-Related Disease (IgG4-RD) | Zenas BioPharma, Inc. | BLA | 8-K filed Nov 5, 2026 |
| in 192 days | KHINDIVI | sNDA | 8-K filed Nov 5, 2026 | |
| in 194 days | VOXZOGOhypochondroplasia | sNDA | 10-Q filed Nov 3, 2026 | |
| in 209 days | UGN-103recurrent low-grade intermediate risk NMIBC | NDA | 10-Q filed Nov 4, 2026 | |
| in 219 days | ralinepagPAH | Liquidia Corp | NDA | 10-Q filed Nov 10, 2026 |
Advisory Committee Meetings Ahead
Meetings FDA has noticed in the Federal Register, soonest first| Meeting | Committee | On the agenda | Submitted by |
|---|---|---|---|
| Microbiology Devices Panel | The meeting presentations will be heard, viewed, captioned, and recorded through an online teleconferencing and/or video conferencing platform. On November 19, … | — |
Recent Decision Dates
Dates in the last 90 days, newest first. A passed date is not a decision: check the drug's page or the company's later filings.| 3 days ago | MYQORZOhypertrophic cardiomyopathy | sNDA | 8-K filed May 5, 2026 | |
| 3 days ago | ivonescimab | Summit Therapeutics Inc. | BLA | 8-K filed Jul 23, 2026 |
| 16 days ago | mitapivatsickle cell disease | sNDA | 10-Q filed Jul 30, 2026 | |
| 18 days ago | INO-3107recurrent respiratory papillomatosis | Inovio Pharmaceuticals, Inc. | BLA | 10-Q filed Aug 12, 2026 |
| 22 days ago | bepirovirsen | — | 10-Q filed Jul 29, 2026 | |
| 31 days ago | Phentolamine Ophthalmic Solution 0.75%presbyopia | Opus Genetics, Inc. | sNDA | 8-K filed Mar 10, 2026 |
| 48 days ago | apitegromab | BLA | 10-Q filed Aug 6, 2026 | |
| 51 days ago | relutrigineSCN2A and SCN8A developmental and epileptic encephalopathies | Praxis Precision Medicines, Inc. | NDA | 10-Q filed Nov 9, 2026 |
| 52 days ago | zilurgisertibfibrodysplasia ossificans progressiva | NDA | 8-K filed Aug 5, 2026 | |
| 56 days ago | zilganersen | — | 10-Q filed Jul 29, 2026 | |
| 59 days ago | UX111 (rebisufligene etisparvovec)Sanfilippo syndrome type A (MPS IIIA) | BLA | 8-K filed Aug 4, 2026 | |
| 60 days ago | zidesamtinibTKI pre-treated locally advanced or metastatic ROS1-positive non-small cell lung cancer | NDA | 10-Q filed May 7, 2026 | |
| 67 days ago | Pixclara | — | 6-K filed Aug 20, 2026 | |
| 82 days ago | bictegravir and lenacapavirvirologically suppressed HIV | NDA | 10-Q filed Aug 6, 2026 | |
| 84 days ago | Ziihera (zanidatamab-hrii)first-line treatment of HER2-positive locally advanced or metastatic GEA, including cancers of the stomach, gastroesophageal junction and esophagus, in combination with chemotherapy, with or without tislelizumab | Zymeworks Inc. | sBLA | 8-K filed Aug 6, 2026 |
| 85 days ago | LEQEMBI IQLIK (lecanemab) | sBLA | 10-Q filed Jul 29, 2026 | |
| 86 days ago | DTX401GSDIa | BLA | 8-K filed Aug 4, 2026 |
Read weekly from companies' 8-K, 6-K and 10-Q filings. A language model reads each sentence for the product and date; a date is listed only when the product and the date both appear in the sentence it came from, and the newest filing wins, so an extension replaces the old date. SEC EDGAR full-text search · Updated Nov 17, 2026
About this data
What a PDUFA date is
Under the Prescription Drug User Fee Act, FDA commits to act on most applications by a goal date: about ten months after filing for a standard review and six for a priority review, counted from when FDA accepts the application. FDA can approve before the date, extend it by three months after a major amendment, or issue a complete response letter instead of an approval. A date is a target, not a promised decision.
What this calendar misses
Only dates a company put in an SEC filing. Private companies, companies outside SEC reporting and many supplemental applications never disclose theirs, and some companies give only a quarter. FDA's own advisory committee calendar is here; published decisions FDA has explained are in the complete response letters.